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1. Introduction
   Bacterial vaginosis (BV), the most common cause of 
vaginal discharge among women in reproductive age[1], is 
indeed a change in the normal vaginal flora characterized 
by a reduction or absence of the hydrogen-peroxide 
producing lactobacilli and an overgrowth of other bacteria, 
especially anaerobic species. It is associated with several 
complications, including sexually transmitted diseases and 
abnormal cervical cytology[2].
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   Drug of choice for treatment of BV is metronidazole[2]. 
Its success rate is about 70 to 80 percent[3], but in 30% of 
patients with an initial response to treatment, the disease 
will recur within three months[4]. Also, its use is associated 
with some side effects such as drowsiness, dizziness, nausea, 
transient neutropenia, peripheral neuropathy and vaginal 
candidiasis[5]. In addition, allergy and resistant to the drug is 
seen in some patients[4,6]. 
   In recent years, due to people’s interest in herbal 
medicines and the high prevalence of side effects of 
chemical drugs, herbal medicine has had a growing trend[7]. 
Many studies have shown the efficacy and safety of some 
herbal medicines in different disorders including BV[8]. 
   Hypericum perforatum L. (H. perforatum) which is 
commonly known as St John’s wort is one of the plants that 
has attracted the attention of a lot of researchers nowadays, 
due to its numerous benefits. It is now one of the most widely 
used herbal medicines throughout the world[9]. It belongs 
to Hypericaceae family and is herbaceous and perennial 
plant. Its flowering branches are medicinally valuable[10]. 
This plant contains many compounds and chemical 
substances such as anthraquinone (naphthodianthrones) 
derivatives, flavonoids, pernilated phloroglucinols, tannins, 
some phenols, volatile oils, hyperforin and hypericin. 
Standardization of the plant and the industrial medicines 
produced from this plant are carried out based on two 
hypericin and pseudohypericin materials[11].
   This plant is traditionally used for the treatment of 
inflammation of the bronchi and urogenital tract, biliary 
disorders, common cold, migraine headaches, sciatica, 
dyspepsia, malaria, and topically for cuts, burns and skin 
ulcers. Also, it is used for treatment of menstrual disorders, 
elimination of leukorrhea and bladder irritation and as an 
antidepressant, a diuretic and an analgesic[10]. In addition, 
different pharmaceutical dosage forms of this plant are 
prepared by some pharmaceutical companies like Goldarou 
in Iran and Esensa d.o.o. company in Serbia[12,13], and are 
recommended for treatment of different disorders including 
microbial infection of skin and mucosa. In the study 
setting, this plant in different forms including brewed or 
incense forms is traditionally used to treat different types of 
infections including bacterial vaginosis, and most people are 
very satisfied with it.
   No serious adverse event has been reported in human 
studies using H. perforatum (in form of oral drop, oral 
tablet, and topical ointment) on some other problems 
like scalp wound[14], premenstrual syndrome[15], pain of 
caesarean section[16]. Also, no side effect has been reported 
in its medicinal use[14-16], but there are probability of 
increasing sensitivity to light and some complications such 
as gastrointestinal irritations, allergic reactions, tiredness 
and sleep disorders in its use in larger amounts which are 
transient[10].
   According to our bibliographic studies in the literature, 
there is no study on antibacterial effect of H. perforatum in 
human. However, in-vitro studies showed that its extract has 
potent anti-bacterial effects[10,17-19].
   The aim of this study was to assess effect of H. perforatum 
vaginal gel compared with that of metronidazole in BV 
in terms of initial response to treatment and preventing 
recurrence (primary outcomes) and also patient complaints 
(secondary outcomes).
2. Materials and methods
2.1. Participants and setting
   This double-blind double-dummy randomized 
controlled trial was conducted on 162 married women 
aged 18-49 years old with bacterial vaginosis attending 
health centres in Jolfa and Hadishahr, two small cities 
located in East Azerbaijan province, Iran. The excluding 
criteria were pregnancy; lactation; smoking; suffering 
from sexually transmitted infections, candidiasis or heart 
or kidney diseases; expected menstruation within next 10 
d; abnormal vaginal bleeding; having sexual intercourse, 
douching and vaginal drug use within the past 48 h; history 
of drug hypersensitivity to metronidazole; use of combined 
oral contraceptives, immune-suppressive, broad-spectrum 
antibiotics, anti-prostaglandins and anticoagulant drugs 
during the past month.
2.2. Recruitment and data collection
   Final decision for eligibility and all clinical examinations 
of participants (including discharge sampling, whiff test and 
the pH measurement) were carried out by one investigator 
[Zahra Mohammadzadeh (ZM), one of co-authors], a midwife 
with long clinical experience working at the Jolfa social 
security clinic in the mornings and at a private office in the 
evenings. Midwives working at public health centres of the 
two cities referred potential eligible subjects to her working 
places after a brief explanation of research. 
   The investigator completed a questionnaire containing 
questions on demographic and reproductive characteristics 
and patient complaints by interview, after a more thorough 
description of objectives and study method, eligibility 
assessment and getting patient verbal informed consent. 
Then, she examined vagina and cervix regarding the signs of 
inflammation and discharge characteristics (colour, odour, 
consistency and rate of discharge) and the initial rule out of 
sexually transmitted infections and candidiasis. 
   In patients with a high risk of bacterial vaginosis who had 
no signs of other vaginal infections, discharge in the lateral 
vaginal walls and posterior fornix were taken by two sterile 
swabs. Discharge on the first swab was placed in a sterile tube 
containing 0.2 mL normal saline solution and was sent to 
the laboratory to examine the clue cells and trichomoniasis. 
Discharge on the second swab was placed on a clean glass 
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slide and after adding one drop of 10% potassium hydroxide 
(KOH) solution the slide was immediately investigated 
regarding the fishy odour (whiff test). Then it was covered 
with a cover slip and viewed directly under microscope 
for candidiasis. Moreover, pH of vaginal discharge was 
measured by a pH-meter tape (Merck, Germany) having 0.5 
precision. 
   All slides were investigated by one laboratory specialist 
with no knowledge of the results of clinical assessment. 
The laboratory results were reported to ZM on the day of 
sampling. 
   At the same night she called the diagnosed infected 
persons and invited them to come to the social security 
clinic the next morning or to her private office in the evening 
to receive the treatment. 
   The diagnosis criteria of BV was based on the presence 
of three out of four Amsel criteria, i.e. homogeneous, thin, 
greyish-white or milky vaginal discharge; vaginal pH greater 
than 4.5; positive whiff test and presence of clue cells on 
microscopy. This method has high and acceptable sensitivity 
and specificity in BV diagnosis[20]. 
   Content validity of the data about collection tool was 
determined by eight experts. Vaginal discharge pH of 10 
subjects were measured independently by two people (ZM 
and a gynaecologist) to determine the reliability of the pH-
meter. Moreover, clinical examination for the 10 subjects 
was performed by two people and two separate vaginal 
samples were prepared from 10 subjects and were sent to 
the laboratory with two different names. There was over 90% 
consensus in all cases.
2.3. Randomization and intervention
   The participants were randomly allocated into two groups 
using permuted block method with block sizes of 4 and 
6 and allocation ration of 1:1 after obtaining an informed 
written consent. Allocation sequence was identified using 
computerized random numbers by a person not involved in 
recruitment, data collection and analysis. All participants 
got two 40-gram tubes of vaginal gels to use for 5 d; one 
tube of 3% H. perforatum and one tube of placebo of 
metronidazole, or one tube of 0.75% metronidazole and 
one tube of placebo of H. perforatum. The gels had been 
placed in identical sequentially numbered packages which 
were given to the participants in their recruitment order in 
the study. Reason for the placebo use was that it was not 
possible to make the two drugs identical in order to maintain 
blinding. The placebos were identical with their main drugs 
in every aspect except the active ingredient. 
   The participants were instructed to use the gels vaginally 
twice a day; one full applicator (5 g) each time, once in the 
mornings from one tube and once at nights from the other 
tube. They were also told to abstain from sexual intercourse 
or use condoms for 10 to 12 d, avoid douching and use no 
antibiotic or other vaginal creams or tablets during treatment 
period. The patients were asked to fill up a diary about drug 
use and any side event and to inform any serious side event 
immediately by phone or in person. 
2.4. Follow-up visits
   The participants were asked to attend 10 to 12 d after 
starting the treatment to be re-assessed and deliver drug 
empty tubes. In case of negative response to treatment 
(positive result of at least two out of four Amsel criteria at the 
first follow-up)[21], patients received the routine treatment 
with metronidazole tablets 500 mg, twice a day for 7 d. In 
case of treatment success, patients were notified by phone 
and asked to revisit 30 to 35 d after starting the treatment 
while abstaining from sexual intercourse for 48 h prior to the 
visit. At the follow-up visits, patient complaints were asked 
and clinical and laboratory assessments were done like the 
baseline stage. 
2.5. Ethical considerations
   Participant recruitment was started after approving 
research project scientifically by the Research Center of 
Infectious & Tropical Diseases (code: 9108) and ethically by 
ethics committee of Tabriz University Medical Sciences- 
Iran (code: 9060, date: Dec 25, 2011) and registering in Iranian 
registry controlled trial with IRCT201112063706N9 code (http://
apps.who.int/trialsearch/trial.aspx?trialid=IRCT201112063706
N9).
   Written informed consent was got from all participants. In 
addition, prior to the study, the prepared gel was used by 
five members of the research group’s close relatives with 
careful observance to make sure of lack of any serious side 
effects.
2.6. Drug preparation
   In this study, we used 3% concentration of H. perforatum 
L. vaginal gel because it was used for the first time 
on human mucosa. In a study using H. perforatum L. 
concentrations of 2%, 5% and 20%, it was found that the 
effect of 2% concentration is better in rabbit’s wound 
healing[22]. 
   The H. perforatum plant was purchased from a person 
with full knowledge of regional medicinal plants who 
had handpicked it from the Hadishahr region. The plant 
identification was confirmed by an expert working in 
medicinal plants research centre of the Tabriz University 
of Medical Sciences. In industrial pharmacy laboratory of 
pharmacy school of this university, the branches of the 
flowering plant (flowering tops) were soaked in 70% hydro-
alcoholic solution and was stirred on a shaker for 72 h. After 
this period, the extract was filtered by paper filter and the 
remaining pulp was shaken again in the hydro-alcoholic 
solution for another 72 h and its extract was separated and 
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added to the previous extract. The obtained extract was 
placed in the rotary evaporator at 40 °C till all the solvent 
was removed and a dry powder was left. The obtained 
powder was converted into fine particles by milling. 
   For preparing the gel, sodium carboxymethylcellulose 
(4% w/w) was used. For this purpose, firstly the conserved 
water was prepared using the methyl and propyl-paraben. 
An appropriate amount of extracted powder was added to 
the water and was stirred until it was completely dissolved. 
Then sodium carboxymethylcellulose was added and stirred 
to obtain a gel with suitable viscosity. The phosphoric acid 
1N was added drop by drop to the gel until the pH was 
adjusted to 4. The obtained gel was poured in sterile tubes 
which did not bear any names by filling machine.
   The metronidazole vaginal gel was produced by Behvazan 
Pharmaceutical Company, Iran. It was re-filled in tubes that 
were similar to H. perforatum L. tubes.
2.7. Outcomes 
   The primary outcomes were success rate on Day 10 to 
12 (the positive of one or none of Amsel’s criteria) and the 
recurrence rate (positive of at least two out of four Amsel 
criteria) on days 30 to 35 after starting treatment[21]. Secondary 
outcomes included each of the patient complaints, treatment 
satisfaction level and adverse events.
2.8. Sample size and statistical analysis
   The sample size was calculated using Stata software 
version 9.2 (Statasoft, Inc., Tula, USA). Considering 80% 
treatment rate with metronidazole, 5% one-tailed type I 
error, power of 80% and a 10% probable drop in the sample, 
the required sample size were calculated to be 80 for each 
group to detect a minimum difference of 20% in treatment 
rate.
   Data analysis was performed using SPSS-version 13 
software. Chi-square test, Fisher’s exact test or binary 
logistic regression were used to compare the two groups in 
terms of frequency of initial positive response to treatment 
and recurrence rate, clinical and laboratory signs and 
patient complaints.
3. Results
3.1. Recruitment and follow-up
   The participants were recruited from Febuary to September 
2012 and followed-up until October 2012. All participants 
attended the first follow-up on 10th-12th day. Fifteen out 
of 82 people in the H. perforatum group and 12 out of 80 
in the metronidazole group who got oral metronidazole on 
10th-12th day follow-up due to negative response to the 
treatment were excluded in the second follow up and one 
person from the H. perforatum group did not attend the 
second follow up due to operation of low back disk hernia 
(She expressed her satisfaction with the treatment on the 
phone). Therefore, 66 participants in H. perforatum group 
and 67 participants in metronidazole group were assessed at 
the second follow-up on 30th-35th day.
3.2. Baseline characteristics
   At the baseline, the reproductive and demographic 
characteristics, patient complaints, clinical observations 
and Amsel criteria of the two groups were similar. The 
mean age of the subjects was 33.7 (SD: 7.5) years and age at 
their first marriage was 19.4 (SD: 4.2). Almost four-fifth of 
the participants had primary or secondary education and 
91% of them were housewives (Table 1). All participants in 
both groups had thin, homogeneous, grey and abundant 
discharge; vaginal pH greater than 4.5 and positive clue cell. 
All except four had positive whiff test (Table 2). The most 
common complaints of the subjects were malodorous vaginal 
discharge (93%), burning during intercourse (44%), Itching 
(38%) and lower abdominal pain (35%) (Table 3). 
Table 1
Baseline characteristics of the participants by study groups.
Characteristics
Hypericum 
(n=82)
Metronidazole 
(n=80)
Age (years) 33.4依7.8 34.1依7.2
Age at marriage (years) 19.0依4.3 19.9依4.0
Educational level
Illiterate  8 (10%) 8 (10%)
Primary (1-8 years) 37 (45%) 32 (40%)
Secondary (9-12 years) 32 (39%) 32 (40%)
University 5 (6%) 8 (10%)
Occupation (Housewife) 76 (93%) 71 (89%)
Family income less than expenses 11 (13.4%) 11 (13.8%)
Number of pregnancy 2.5 (1.9) 2.6 (2.0)
Number of vaginal delivery 1.6 (1.8) 1.4 (1.7)
History of abortion 25 (31%) 30 (38%)
Time of the last delivery (<3 years ago) 14 (19%) 18 (24%)
History of vaginal infection needed treatment 60 (73%) 56 (70%)
The data are given as n (%) unless otherwise is specified. There were no 
significant statistically difference between the groups in terms of any of the 
characteristics.
3.3. Outcomes
   At the 10th-12th day follow up, the positive response 
to treatment was observed at 82% of H. perforatum group 
and 85% of the metronidazole group and there was no 
statistically significant difference between the groups 
[relative risk (RR) 0.9, 95% confidence interval (CI) 0.6 
to 1.3, P=0.574]. Compared with metronidazole group, 
in H. perforatum group the frequency of homogenous 
discharge was significantly less (4% vs. 15%, P=0.013) and 
the frequency of pH>4.5 was more (60% vs. 36%, P=0.003). 
The two other Amsel criteria, the presence of clue cell and 
positive whiff test, were also significantly decreased in the 
both groups compared to the baseline but no significant 
difference was found between the groups in these criteria 
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(P=0.153, P=0.310, respectively) (Table 2). 
   At the 30th-35th day follow-up, the recurrence rate was 
9% in H. perforatum group and 13% in metronidazole group 
(RR 0.8, 95% CI 0.4 to 1.3, P=0.447) among the participants 
with initial positive response to the treatment. There was 
no statistically significant difference between the groups 
regarding any of the Amsel criteria (P>0.05) (Table 2). 
   At the both follow-ups, there was no statistically 
significant difference (P>0.05) between the two groups 
regarding the patient complaints, except itching. Compared 
with metronidazole group, in H. perforatum group itching 
was significantly less at both the first follow-up (16% 
vs. 5%, P=0.026) and the second follow-up (43% vs. 12%, 
P<0.001) (Table 3).
   Overall satisfaction with treatment was asked from the 
participants at the second follow-up with a 5-points Likert 
scale question. In H. perforatum group, 67% were very 
satisfied, 19% satisfied, 11% unsure and 3% dissatisfied. In 
metronidazole group, these percentages were 35%, 33%, 13% 
and 19%, respectively and Mann-Whitney U test indicated 
higher satisfaction in the H. perforatum group (P=0.001).
3.4. Side events
   Eleven patients in the H. perforatum group had 
complaint of vaginal irritation during the first day of taking 
the gels. Nausea, vomiting and dizziness was reported 
by one and vaginal dryness by two of the participants 
of the intervention group. In the metronidazole group, 
vaginal burning during the drug use was reported by two 
participants, nausea by two, vomiting by one, dizziness 
by two, vaginal dryness by four and metallic taste by one. 
In addition, 16 subjects in H. perforatum group and one 
participant in metronidazole group were very satisfied with 
the recovery of previous severe low back pain.
4. Discussion
   To the best of our knowledge, this study is the first 
research performed regarding the effect of H. perforatum L. 
on BV in human. Its results revealed that effect of 3% vaginal 
gel of H. perforatum in treatment and prevention of disease 
relapse is similar to 0.75% metronidazole vaginal gel, it was 
well tolerated by people without having any significant side 
effects and most people were satisfied with it.
   The results of this study are consistent with the results 
of the in-vitro studies assessed antibacterial effect of 
Hypericum extract in laboratory[17,23-27].  
   In the study by Milosevic et al. the antimicrobial effect 
of the ethanol extract of H. perforatum L. was shown on the 
investigated ten types of bacteria[25]; eight types of Gram 
negative bacteria (Pseudomonas fluorescens, Pseudomonas 
phaseolicola, Pseudomonas glycinea, Erwinia carotovora, 
Enterobacter cloacae, Klebsiella pneumoniae, Agrobacterium 
tumefaciens, Azotobacter chrococcum) and 2 types of Gram 
positive bacteria (Bacillus mycoides, Bacillus subtilis). Also 
in a study by Feyzioğlu et al.[26], hypericin was effective on 
the Staphylococcus aureus ATCC 29213 and Staphylococcus 
epidermidis ATCC 12228.  
Table 2
Rate of cure and recurrent of BV and each of Amsel criteria by the study groups.
Outcome variables
Hypericum Metronidazole Day 10-12 Day 30-35
Baseline 
(n=82)
Day 10-12 
(n=82)
Day 30-35 
(n=66)
Baseline
 (n= 80)
Day 10-12
 (n= 80)
Day 30-35
 (n= 68)
RR (95% CI) P RR (95% CI) P
Primary outcomes
Cure of BV - 67 (82%) - - 68 (85%) - 0.9 (0.6 to 1.3) 0.574 - -
Recurrent of BV - - 6 (9%) - -  9 (13%) - - 0.8 (0.4 to 1.3) 0.447
Amsel criteria 
Homogenous discharge  82 (100%) 3 (4%) 1 (2%)   80 (100%) 12 (15%)  7 (10%) 0.4 (0.1 to 1.0) 0.013 0.2 (0.4 to 1.5) 0.062
Presence of clue cells  82 (100%) 22 (27%)   8 (12%)   80 (100%) 14 (18%)  8 (12%) 1.3 (0.9 to 1.8) 0.153 1.0 (0.6 to 1.7) 1.0
Positive whiff test 81 (99%)   8 (10%) 1 (2%) 77 (96%) 12 (15%) 2 (3%) 0.8 (0.4 to 1.3) 0.310 0.7 (0.1 to 3.4) 1.0
pH>4.5   82 (100%)  49 (60%)  21 (32%)   80 (100%) 29 (36%) 20 (29%) 1.6 (1.2 to 2.3) 0.003 1.1 (0.7 to 1.5) 0.852
RR: Relative risk; The data are given as n (%); Chi-squared or Fisher’s exact test were used for the between groups comparisons.
Table 3
Frequency of patient complaints before and after intervention by the study groups.
Patient complaints
Hypericum Metronidazole Day 10-12 Day 30-35
Baseline 
(n=82)
Day 10-12 
(n=82)
Day 30-35 
(n=66)
Baseline 
(n=80)
Day 10-12 
(n=80)
Day 30-35
 (n=68)
OR (95% CI) P OR (95% CI) P
Malodor discharge 77 (94%) 3 (4%) 2 (3%) 74 (93%) 2 (3%) 3 (4%) 1.5 (0.2 to 9.0) 0.684 0.7 (0.1 to 4.2)  0.676
Itching 33 (40%) 4 (5%)   8 (12%) 28 (35%) 13 (16%) 29 (43%) 0.3 (0.1 to 0.9) 0.026 0.2 (0.1 to 0.4) <0.001
Dysuria 13 (16%) 0 (0%) 1 (2%) 7 (9%) 4 (5%) 0 (0%) -  0.057
* -    0.493*
Burning 17 (21%) 3 (4%) 1 (2%) 14 (18%) 1 (1%) 0 (0%) 2.9 (0.3 to 28.4) 0.371 -    0.493
*
Burning during intercourse 37 (45%) 6 (7%) 2 (3%) 34 (43%) 4 (5%) 0 (0%) 1.6 (0.4 to 6.1) 0.528 -    0.241
*
Lower abdominal pain 29 (35%)   9 (11%) 4 (6%) 27 (34%)   8 (10%)   7 (10%) 1.1 (0.4 to 3.0) 0.873 0.6 (0.2 to 2.0)   0.370
Dyspareunia 11 (13%) 2 (2%) 2 (3%) 6 (8%) 0 (0%) 0 (0%) -  0.497
* -    0.241*
OR: Odds ratio; The data are given as n (%); 
*: For the between groups comparisons, Fisher’s exact text was used for these ones and logistic regression adjusted 
for baseline values for the others.
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   Furthermore, in a study by Yousuf et al.[23], antimicrobial 
activity of methanol extract of H. perforatum leaves 
was shown against all of the 6 bacteria under study 
(Staphylococcus epidermidis MTCC- 435, Bacillus subtilus 
MTCC-441, Proteus vulgaris MTCC-321, Staphylococcus 
aureus, Salmonella typhi,  Escherichia coli).
   Also, in studies by Zdunić  et al.[28], and Paterniti et al.[29], 
the anti-inflammatory effect of H. perforatum L. extract 
and in Abdel-Salam’s study[30], its anti-edematogenic and 
analgesic effects on rats have been shown which might be 
related to the antimicrobial effect of this plant.
   Occurring no serious side event in H. perforatum vaginal 
gel users in this study is similar to results of previous studies 
using other forms of this herb on human subjects affected 
with other disorders[14-16].
   Blinding the participants and the people involved in the 
recruitment, data collection, outcome assessment and data 
analysis, no attrition in the first follow-up and follow-up of 
all but one participant in the second stage can be mentioned 
as strengths of this study. Larger samples size, compared to 
most other studies on bacterial vaginosis, is another strength 
point of this study.
   Not using Nugent method as the golden standard for 
diagnosis and treatment, as well as short follow-up period 
(only 1 month) could be mentioned as the study limitations. 
Therefore, we suggest other studies in this area with 
longer follow-up and using diagnosis methods with higher 
sensitivity and specificity in other settings. 
   Responses to the plant may occur with delay in some 
people. However, it was not possible to assess the potential 
delayed effect. Due to ethical issues (no previous information 
on the efficacy of the treatment on human beings), in this 
study all the participant who did not have positive response 
on 10th-12th days follow-up (27 of 162 participants) were 
treated with oral metronidazole without knowing the 
participants’ group. According to the results of this study 
about of similar success rate in the two groups, re-treatment 
could be delayed until the following month in subsequent 
studies to determine the potential delayed effect.
  In conclusion, the findings of this study showed that 3% 
H. perforatum vaginal gel is effective in treatment of the 
patients suffering from bacterial vaginosis and decreasing 
their complaints. Given the high acceptance by patients 
and lack of any serious side effects, it seems that this gel 
could be used as an effective treatment option in bacterial 
vaginosis, especially in drug resistance cases and also 
for those interested in herbal therapies. However, further 
studies are needed for its public use.
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Comments 
Background
   Bacterial vaginosis is the most common cause of vaginal 
discharge in women. It can cause bothersome symptoms, 
and also increase the risk of acquiring serious sexually 
transmitted infections. The metronidazole is one of the 
most effective treatments. Because of the side effects of this 
antibiotic, we need an alternative.
  
Research frontiers
   This research focuses on the study of the effect of H. 
perforatum compared with metronidazole in bacterial 
vaginosis. This work was carried out on 162 married women 
18-49 years old. The whiff test is the main test used to 
determine bacterial vaginosis.
Related reports
   Russo et al. (2013) have published a review article about 
H. perforatum entitled Pharmacokinetic, mechanism of 
action, tolerability, and clinical drug–drug interactions. H. 
perforatum extracts appear to be well tolerated. However, 
on the basis of our knowledge, there are few researches that 
are interested in this kind of study on bacterial vaginosis 
(Simbar et al., 2008).
Innovations and breakthroughs
   Antibiotics used against bacterial vaginosis are very 
limited. A few antibiotic remedies are routinely used and 
include: metronidazole, clindamycin, or tinidazole. It 
requires very effective and safe therapeutic alternatives. 
The innovation in this paper is the use of H. perforatum 
extracts as an alternative against bacterial vaginosis (in 
vivo).
Applications
   We can apply this natural product (H. perforatum vaginal 
gel) in pharmaceutical industry and in the treatment of 
bacterial vaginosis.
Peer review
   This work represents an important study. These 
researchers have tested H. perforatum vaginal gel on 162 
married women 18-49 years old. They found that this gel 
exhibits a very interesting activity against the bacteria 
responsible for bacterial vaginosis. In all the cases, the 
originality of this work gave us a great satisfaction on the 
Sakineh Mohammad-Alizadeh-Charandabi et al./Asian Pac J Trop Biomed 2014; 4(11): 896-902902
importance of this study in a number of biological and 
medicine fields.
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